Adoram Therapeutics was incorporated in 2022 as a spin-off from the University of Geneva. Founders and Board members include CEO Dr. David Pejoski, CSO Dr. Hesham Hamed, and drug discovery advisor Prof. Leonardo Scapozza. Together with a team of scientists; Aurélie Gouiller, Camille Suess, Sébastien Tardy, Margot Boujut, and Margaux Héritier, they are developing a suite of small molecule allosteric modulators for different cancer and non-cancer indications based around GPCR drug targets, the largest class of receptors in the human genome.
Small molecule drugs with an allosteric mode of action are sought-after in drug development because of their clear advantages over conventional drugs, such as increased potency as well as safety.
Location: Switzerland, Geneva, Lancy
Employees: 1-10
Founded date: 2022
Investors 2
| Date | Name | Website |
| - | Venture Ki... | venturekic... |
| 25.03.2024 | VentureLab | venturelab... |
Mentions in press and media 2
| Date | Title | Description | Source |
| 27.03.2024 | Ten startups on a business voyage in Boston | Selected from over 70 applications by a jury of investors and biotech experts, the ten startups sel... | startuptic... |
| 11.04.2023 | Startups leveraging allosteric biochemistry for cancer immun... | Adoram Therapeutics: Leveraging allosteric biochemistry for patients Existing therapies are not effi... | venturekic... |